ClinicalTrials.gg
CompletedNCT02337829Updated Jul 21, 2026Results posted

Acalabrutinib in Patients With Relapsed/Refractory and Treatment naïve Deletion 17p CLL/SLL

A Phase 2 interventional study of Acalabrutinib (Arm A) and Acalabrutinib (Arm B) in Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma, sponsored by Acerta Pharma BV. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-21.

Sponsored by Acerta Pharma BV (part of AstraZeneca) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
48
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 39 studies testing acalabrutinib in Leukemia, Lymphocytic, Chronic, B-Cell — 11 open to participants now, 28 under way, 6 of them phase 3. acalabrutinib · Leukemia, Lymphocytic, Chronic, B-Cell.

Enrollment
25th of 39
48 · median 61
Started
2015
with 3 others
Phase 2
22 of 39
8 open now
Registered
2nd of 39
by date
Lead sponsor
9 of 39
Acerta Pharma BV

Among the 39 studies testing acalabrutinib in Leukemia, Lymphocytic, Chronic, B-Cell, this one is the 25th largest by enrollment, is one of 4 that started in 2015, is one of 22 in phase 2, and was the 2nd registered.

Leukemia, Lymphocytic, Chronic, B-Cell

2,036 studies on the registry are indexed under Leukemia, Lymphocytic, Chronic, B-Cell; 236 are open to participants now.

Browse Leukemia, Lymphocytic, Chronic, B-Cell studies →

Open to participants now

11 of the 39 studies testing acalabrutinib in Leukemia, Lymphocytic, Chronic, B-Cell are open now, in 12 countries. Recruiting first, the newest first:

6 more — sign in →

By country, each count listing its studies:

All 11 open studies →

About acalabrutinib

acalabrutinib: first FDA approval 2017 (CALQUENCE), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 187 Leukemia, Lymphocytic, Chronic, B-Cell studies recruiting now, 150 (80%) set no upper age limit and 15 (8%) stop at 75 or younger; 17 take children under 18; 12 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 39 studies testing acalabrutinib in Leukemia, Lymphocytic, Chronic, B-Cell, or all of them as a file.
02

Study summary

This study is to determine the response to acalabrutinib in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).

Read the detailed description

To investigate the safety and efficacy of acalabrutinib for patients with CLL/SLL that have relapsed/refractory disease or treatment naive deletion 17p.

03

Conditions studied

  • Chronic Lymphocytic Leukemia
  • Small Lymphocytic Lymphoma

Keywords

  • Relapsed/refractory CLL
  • Btk
  • Leukemia
  • Lymphocytic
  • Lymphoma
  • Chronic Lymphocytic Leukemia (CLL)
  • Small Lymphocytic Lymphoma (SLL)
  • ACP-196
  • Acalabrutinib
  • Treatment naive CLL
  • 17p deletion
  • TP53 mutation
  • NOTCH1 mutation
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men and women 18 years of age and older with confirmed disease.
  • Active disease as defined by at least one of the following (IWCLL consensus criteria):

    • Weight loss ≥10% within the previous 6 months
    • Extreme fatigue
    • Fevers of greater than 100.5ºF for ≥2 weeks without evidence of infection
    • Night sweats for more than one month without evidence of infection
    • Evidence of progressive marrow failure as manifested by the development of, or worsening of, anemia and/or thrombocytopenia
    • Massive or progressive splenomegaly
    • Massive nodes or clusters or progressive lymphadenopathy
    • Progressive lymphocytosis with an increase of >50% over a 2 month period, or an anticipated doubling time of less than 6 months
    • Compensated hemolysis
  • CLL or treatment naïve CLL patients with 17p deletion, TP53 mutation, or NOTCH1 mutation
  • Agreement to use acceptable methods of during the study and for 30 days after the last dose of study drug if sexually active and able to bear or beget children.
  • Willing and able to participate in all required evaluations and procedures in this study protocol including swallowing capsules without difficulty and serial .
  • Ability to understand the purpose and risks of the study and provide signed and dated and authorization to use protected health information (in accordance with national and local subject privacy regulations).

Exclusion criteria

Exclusion Criteria:

  • Radiotherapy, radioimmunotherapy, biological therapy, chemotherapy, or products in the last 4 weeks.
  • Richter's transformation. hemolytic anemia or thrombocytopenia requiring therapy. Impaired hepatic function
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
48 participants (actual)

Study arms

  • Experimental
    Arm A

    Subjects will be randomized to receive 1 of 2 dosing regimens: 1) acalabrutinib, dose A once daily; or 2) acalabrutinib, dose B twice daily.

    Drug: Acalabrutinib (Arm A) · Drug: Acalabrutinib (Arm B)

  • Experimental
    Arm B

    Subjects will be randomized to receive 1 of 2 dosing regimens: 1) acalabrutinib, dose A once daily; or 2) acalabrutinib, dose B twice daily.

    Drug: Acalabrutinib (Arm A) · Drug: Acalabrutinib (Arm B)

Interventions

  • * A1a) acalabrutinib, dose A daily: biopsy (T) schedule W; * A1b) acalabrutinib, dose A daily: biopsy (T) schedule V. * A2a) acalabrutinib, dose B q 12 hours: biopsy (T) schedule Y; * A2b) acalabrutinib, dose B q 12 hours; biopsy (T) schedule Z

    Also known as: ACP-196

  • B1c) acalabrutinib, dose A daily: biopsy (U) schedule W; • B2c) acalabrutinib, dose B q12 hours: biopsy (U)) schedule Y.

    Also known as: ACP-196

06

What researchers measure

Primary outcomes

  1. Response Based on Overall Response Rate

    The best response to treatment was determined according to International Workshop on Chronic Lymphocytic Leukemia (IWCLL) 2008 criteria incorporating 2012 and 2013 clarifications pertaining to subjects treated with kinase inhibitors. Overall response rate (ORR) was the proportion of subjects who achieved complete response (CR), CR with incomplete marrow recovery (CRi), or partial response (PR) while on treatment before the initiation of new anti-cancer therapy or stem cell transplant.

    Time frame: Cycle 1 (28 Days) to 6 months

07

Results

Posted Aug 18, 2021

Participant flow

Participant flow — Overall Study
MilestoneAcalabrutinib 100 mg BID Relapse/RefractoryAcalabrutinib 200 mg QD Relapse/RefractoryAcalabrutinib 100 mg BID Treatment NaiveAcalabrutinib 200 mg QD Treatment Naive
Started1814610
Completed0000
Not completed1814610
Withdrew: Death0100
Withdrew: Study terminated by sponsor121056
Withdrew: Discontinued for other reasons6314

Outcome measures

PrimaryResponse Based on Overall Response Rate

The best response to treatment was determined according to International Workshop on Chronic Lymphocytic Leukemia (IWCLL) 2008 criteria incorporating 2012 and 2013 clarifications pertaining to subjects treated with kinase inhibitors. Overall response rate (ORR) was the proportion of subjects who achieved complete response (CR), CR with incomplete marrow recovery (CRi), or partial response (PR) while on treatment before the initiation of new anti-cancer therapy or stem cell transplant.

Time frame:
Cycle 1 (28 Days) to 6 months
Reported as:
Count of participants · Participants
Response Based on Overall Response Rate
ParticipantsAcalabrutinib 100 mg BID Relapse/RefractoryAcalabrutinib 200 mg QD Relapse/RefractoryTotal Relapse/Refractory SubjectsAcalabrutinib 100 mg BID Treatment NaiveAcalabrutinib 200 mg QD Treatment NaiveTotal Treatment Naive Subjects
Response Based on Overall Response Rate1711286814

Adverse events

Collected over From first dose of study drug until 30 days post last dose for each subject; an average of approximately 38 months.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Acalabrutinib 100 mg BID Relapse/Refractory0/18 (0%)11/18 (61.1%)18/18 (100%)
Acalabrutinib 200 mg QD Relapse/Refractory1/14 (7.1%)8/14 (57.1%)14/14 (100%)
Acalabrutinib 100 mg BID Treatment Naive0/6 (0%)3/6 (50%)6/6 (100%)
Acalabrutinib 200 mg QD Treatment Naive0/10 (0%)5/10 (50%)10/10 (100%)
Most frequent serious events
Showing 10 of 33
Most frequent serious events
EventAcalabrutinib 100 mg BID Relapse/RefractoryAcalabrutinib 200 mg QD Relapse/RefractoryAcalabrutinib 100 mg BID Treatment NaiveAcalabrutinib 200 mg QD Treatment Naive
Cardiac failureCardiac disorders0/180/141/60/10
Upper gastrointestinal haemorrhageGastrointestinal disorders0/180/141/60/10
CholecystitisHepatobiliary disorders0/180/141/60/10
Pneumonia influenzalInfections and infestations0/180/141/60/10
Prostate cancer metastaticNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/180/141/60/10
Squamous cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/182/140/60/10
PyrexiaGeneral disorders2/180/140/60/10
PneumoniaInfections and infestations2/181/140/60/10
Lung adenocarcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)2/180/140/60/10
EnterocolitisGastrointestinal disorders0/180/140/61/10
Most frequent other events
Showing 10 of 362
Most frequent other events
EventAcalabrutinib 100 mg BID Relapse/RefractoryAcalabrutinib 200 mg QD Relapse/RefractoryAcalabrutinib 100 mg BID Treatment NaiveAcalabrutinib 200 mg QD Treatment Naive
ContusionInjury, poisoning and procedural complications11/189/146/66/10
Oedema peripheralGeneral disorders3/184/145/62/10
Pain in extremityMusculoskeletal and connective tissue disorders3/182/145/62/10
HeadacheNervous system disorders12/1810/145/66/10
Influenza like illnessGeneral disorders7/189/143/68/10
DiarrhoeaGastrointestinal disorders7/187/144/64/10
FatigueGeneral disorders4/185/144/63/10
Weight increasedInvestigations5/183/144/62/10
MyalgiaMusculoskeletal and connective tissue disorders8/188/141/65/10
Rash maculo-papularSkin and subcutaneous tissue disorders5/188/141/64/10

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Acalabrutinib 100 mg BID Relapse/RefractoryAcalabrutinib 200 mg QD Relapse/RefractoryAcalabrutinib 100 mg BID Treatment NaiveAcalabrutinib 200 mg QD Treatment NaiveTotal
Mean63.3 ± 9.362.3 ± 7.768.3 ± 10.962.1 ± 8.763.4 ± 8.9
Sex: Female, Male
Sex: Female, Male(Participants)Acalabrutinib 100 mg BID Relapse/RefractoryAcalabrutinib 200 mg QD Relapse/RefractoryAcalabrutinib 100 mg BID Treatment NaiveAcalabrutinib 200 mg QD Treatment NaiveTotal
Female632415
Male12114633
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Acalabrutinib 100 mg BID Relapse/RefractoryAcalabrutinib 200 mg QD Relapse/RefractoryAcalabrutinib 100 mg BID Treatment NaiveAcalabrutinib 200 mg QD Treatment NaiveTotal
Hispanic or Latino00011
Not Hispanic or Latino18146947
Not Reported00000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Acalabrutinib 100 mg BID Relapse/RefractoryAcalabrutinib 200 mg QD Relapse/RefractoryAcalabrutinib 100 mg BID Treatment NaiveAcalabrutinib 200 mg QD Treatment NaiveTotal
American Indian or Alaska Native00000
Asian02002
Black or African American20215
Native Hawaiian or Other Pacific Islander00000
White16124739
Not Reported00022
Region of Enrollment
Region of Enrollment(Participants)Acalabrutinib 100 mg BID Relapse/RefractoryAcalabrutinib 200 mg QD Relapse/RefractoryAcalabrutinib 100 mg BID Treatment NaiveAcalabrutinib 200 mg QD Treatment NaiveTotal
United States181461048
08

Study locations

1 site
  • Research Site
    Bethesda, Maryland 20892, United States
09

References and documents

Publications

  • Alsadhan A, Chen J, Gaglione EM, Underbayev C, Tuma PL, Tian X, Freeman LA, Baskar S, Nierman P, Soto S, Itsara A, Ahn IE, Sun C, Bibikova E, Hartmann TN, Mhibik M, Wiestner A. CD49d Expression Identifies a Biologically Distinct Subtype of Chronic Lymphocytic Leukemia with Inferior Progression-Free Survival on BTK Inhibitor Therapy. Clin Cancer Res. 2023 Sep 15;29(18):3612-3621. doi: 10.1158/1078-0432.CCR-22-3217. PubMed 37227160 ↗
  • Cyr MG, Mhibik M, Qi J, Peng H, Chang J, Gaglione EM, Eik D, Herrick J, Venables T, Novick SJ, Courouble VV, Griffin PR, Wiestner A, Rader C. Patient-derived Siglec-6-targeting antibodies engineered for T-cell recruitment have potential therapeutic utility in chronic lymphocytic leukemia. J Immunother Cancer. 2022 Nov;10(11):e004850. doi: 10.1136/jitc-2022-004850. PubMed 36442911 ↗
  • Sun C, Nierman P, Kendall EK, Cheung J, Gulrajani M, Herman SEM, Pleyer C, Ahn IE, Stetler-Stevenson M, Yuan CM, Maric I, Gaglione EM, Harris HM, Pittaluga S, Wang MH, Patel P, Farooqui MZH, Izumi R, Hamdy A, Covey T, Wiestner A. Clinical and biological implications of target occupancy in CLL treated with the BTK inhibitor acalabrutinib. Blood. 2020 Jul 2;136(1):93-105. doi: 10.1182/blood.2019003715. PubMed 32202637 ↗
  • Alsadhan A, Cheung J, Gulrajani M, Gaglione EM, Nierman P, Hamdy A, Izumi R, Bibikova E, Patel P, Sun C, Covey T, Herman SEM, Wiestner A. Pharmacodynamic Analysis of BTK Inhibition in Patients with Chronic Lymphocytic Leukemia Treated with Acalabrutinib. Clin Cancer Res. 2020 Jun 15;26(12):2800-2809. doi: 10.1158/1078-0432.CCR-19-3505. Epub 2020 Feb 13. PubMed 32054731 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the deidentified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2015 to primary completion in Jun 2020, 65 months.

Results were first posted in Aug 2021, 1 year 1 month after primary completion.

Of 41 industry-sponsored phase 2 interventional studies under Leukemia, Lymphocytic, Chronic, B-Cell, half reached primary completion within 55 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 87. This study's 65 months is above that.

Counting every sponsor, half of 249 studies reached it within 73 months; a quarter within 41 and three quarters within 114.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 19, 2014
First posted
Jan 14, 2015
StartActual
Jan 12, 2015
Primary completionActual
Jun 26, 2020
CompletionActual
Oct 31, 2025
Results first posted
Aug 18, 2021
Last update
Jul 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02337829
Lead sponsor
Acerta Pharma BV
Responsible party
Sponsor
First posted
Jan 14, 2015
Start date
Jan 12, 2015
Primary completion
Jun 26, 2020
Completion
Oct 31, 2025
Results posted
Aug 18, 2021
Last update
Jul 21, 2026

Study contacts

AstraZeneca Clinical Study Information Center
study director · 1-877-240-9479 - information.center@astrazeneca.com

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Acalabrutinib

Start the discussion